Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$52.03 USD

52.03
732,290

+0.17 (0.33%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

Merit Medical (MMSI) Launches New Inflation Device basixALPHA

Merit Medical (MMSI) launches basixALPHA inflation device in the United States for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures.

What You Need to Know From UnitedHealth's (UNH) Latest Outlook

UnitedHealth (UNH) expects the top line to be within the range of $357-$360 billion in 2023.

AmerisourceBergen (ABC) Hits 52-Week High: What's Driving It?

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Boston Scientific (BSX) Posts Positive Post-Market Study Data

The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.

Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?

Cigna (CI) expects its long-term adjusted earnings per share to witness 10-13% average annual growth.

QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification

QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.

Here's Why You Should Retain Stryker (SYK) Stock For Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

Alcon's (ALC) Latest Buyout to Enhance Its Product Portfolio

Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio

Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.

Here's Why You Should Add McKesson (MCK) Stock Right Now

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?

Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.

PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows

PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down

Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.

Here's Why You Should Hold on to Abiomed (ABMD) Stock Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Merit Medical's (MMSI) New Launch to Boost Patient Outcome

Merit Medical's (MMSI) latest addition to its radial portfolio is expected to significantly optimize hemostasis for radial artery procedures.

Why You Should Add UnitedHealth (UNH) to Your Portfolio Now

The improvement of the economy is likely to support UnitedHealth's (UNH) commercial business recovery.

SmileDirectClub (SDC) Q3 Earnings Beat, Gross Margin Dips

Challenges to consumer spending and sustained high inflation continue to impact SmileDirectClub's (SDC) overall expected demand for 2022.

Henry Schein's (HSIC) New Deal to Improve Patient Outcome

Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.

What's in the Cards for Medtronic (MDT) in Q2 Earnings?

Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.

Neogen's (NEOG) Synergize Disinfectant Now Widely Available

Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.